BACKGROUND: Schizophrenia is accompanied by an activation of the immune/inflammatory system. In the present study, the relationships between serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β1 levels and schizophrenia were explored in a group of Taiwanese inpatients. Furthermore, the serum IL-6, TNF-α, and TGF-β1 levels of patients with schizophrenia were compared before and after 1 month of antipsychotic treatment. METHODS: The serum IL-6, TNF-α, and TGF-β1 levels of 34 acute stage schizophrenic patients and 30 healthy control subjects were collected. These levels were again collected in the 34 patients after 1 month of antipsychotic treatment. An analysis of covariance (ANCOVA) adjusted for gender was performed to examine the differences in cytokine levels between the schizophrenic patients and the control group. Repeated measures ANCOVA adjusted for gender was performed to examine the differences in cytokine levels of the schizophrenic patients before and after 1 month of treatment. RESULTS: Using ANCOVA adjusted for gender, significantly increased IL-6 levels were found in schizophrenic patients compared with the control group (p = 0.02), but there were no significant differences in TNF-α and TGF-β1 levels (p = 0.06 and 0.91, respectively). After 1 month of medical treatment, there were no significant differences in IL-6 (p = 0.64), TNF-α (p = 0.48), and TGF-β1 (p = 0.23) levels in the schizophrenic patients, although IL-6 appeared to be normalizing. CONCLUSION: An increase in the IL-6 level may play a role in the pathophysiology of schizophrenia. A larger sample size and a longer period of follow-up are needed to confirm this finding.
BACKGROUND:Schizophrenia is accompanied by an activation of the immune/inflammatory system. In the present study, the relationships between serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β1 levels and schizophrenia were explored in a group of Taiwanese inpatients. Furthermore, the serum IL-6, TNF-α, and TGF-β1 levels of patients with schizophrenia were compared before and after 1 month of antipsychotic treatment. METHODS: The serum IL-6, TNF-α, and TGF-β1 levels of 34 acute stage schizophrenicpatients and 30 healthy control subjects were collected. These levels were again collected in the 34 patients after 1 month of antipsychotic treatment. An analysis of covariance (ANCOVA) adjusted for gender was performed to examine the differences in cytokine levels between the schizophrenicpatients and the control group. Repeated measures ANCOVA adjusted for gender was performed to examine the differences in cytokine levels of the schizophrenicpatients before and after 1 month of treatment. RESULTS: Using ANCOVA adjusted for gender, significantly increased IL-6 levels were found in schizophrenicpatients compared with the control group (p = 0.02), but there were no significant differences in TNF-α and TGF-β1 levels (p = 0.06 and 0.91, respectively). After 1 month of medical treatment, there were no significant differences in IL-6 (p = 0.64), TNF-α (p = 0.48), and TGF-β1 (p = 0.23) levels in the schizophrenicpatients, although IL-6 appeared to be normalizing. CONCLUSION: An increase in the IL-6 level may play a role in the pathophysiology of schizophrenia. A larger sample size and a longer period of follow-up are needed to confirm this finding.
Authors: David I Driver; Afsoon A Anvari; Christina M Peroutka; Rachna Kataria; Jerry Overman; David Lang; Maria Tietcheu; Reggie Parker; Keith Baptiste; Judith L Rapoport; Nitin Gogtay Journal: Am J Psychiatry Date: 2014-04 Impact factor: 18.112
Authors: Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2016-10-17 Impact factor: 4.105
Authors: Dor Mohammad Kordi-Tamandani; Ahmad Reza Bahrami; Raziye Sabbaghi-Ghale-No; Hanieh Soleimani; Tayebe Baranzehi Journal: Mol Biol Res Commun Date: 2016-03